Annovis Bio, Inc. (ANVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc., a Delaware corporation and emerging growth company, on February 12, 2026. The report covers events occurring on February 12, 2026, and serves as a disclosure under Regulation FD.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a press release and does not contain a financial statement or detailed operational metrics.
Material Changes
The filing indicates the issuance of a press release (Exhibit 99.1) on February 12, 2026. The specific content of the press release and any resulting material changes to the company's status are not detailed within the text of this Form 8-K.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. It solely references the attached press release for further information.
Key Facts for Investor Verification
- Verify the content of the press release filed as Exhibit 99.1 to understand the specific event triggering this filing.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Review the New York Stock Exchange listing status for Common Stock under the symbol ANVS.
- Note that no financial data is included in this specific document; refer to the most recent 10-K or 10-Q for financial performance.